In humans, the PONTIAC I study showed that, in T2DM patients without clinical symptoms of cardiac disease and with high BNP levels, intensified therapy with ACEi (100% of the recommended dose) prevented cardiovascular events without changing BNP levels. Here, NPPB is linked to heart disorder.